Antileishmanial efficacy of fluconazole and miltefosine in combination with an immunomodulator - Picroliv

Parasitology Research

Volumn 108, Issue 4, 2011, Pages 793-800

  Shakya, Nishi ^a   Sane, Shraddha A ^a   Gupta, Suman ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; HYDROGEN PEROXIDE; KUTKIN; MILTEFOSINE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE;

AMASTIGOTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HAMSTER; IC 50; IMMUNOMODULATION; LEISHMANIA DONOVANI; LEISHMANIASIS; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; OPTIMAL DRUG DOSE; PHAGOCYTOSIS; PRIORITY JOURNAL; PROMASTIGOTE; UPREGULATION;

ANIMALS; ANTIPROTOZOAL AGENTS; CINNAMATES; CRICETINAE; DRUG THERAPY, COMBINATION; FLUCONAZOLE; GLYCOSIDES; HYDROGEN PEROXIDE; IMMUNITY, CELLULAR; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; PHAGOCYTOSIS; PHOSPHORYLCHOLINE; REACTIVE OXYGEN SPECIES; TREATMENT OUTCOME; VANILLIC ACID;

ANIMALIA; CRICETINAE; LEISHMANIA DONOVANI;

EID: 79956223246     PISSN: 09320113     EISSN: 14321955     Source Type: Journal    
DOI: 10.1007/s00436-010-2230-2     Document Type: Article

References (27)

1. Alrajhi AA, Ibrahim EA, De Vol EB, Khairat M, Faris RM, Maguire JH (2002) A six-week course of oral fluconazole, in a dose of 200 mg daily for 6 weeks, is a safe and useful treatment for cutaneous leishmaniasis caused by L. major. N Engl J Med 346:891-895
2. Arevalo I, Ward B, Miller R (2001) Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. Clin Infect Dis 33:1847-1851 (Pubitemid 33105123)
3. Ashutosh GS, Ramesh SS, Goyal N (2005) Use of L. donovani field isolates expressing luciferase reporter gene in in vitro drug screening. Antimicrob Agents Chemother 49:3776-3783
4. Bhatnagar S, Guru PY, Katiyar JC, Srivastava R, Mukherjee A, Akhtar MS, Seth M, Bhaduri AP (1989) Exploration of antileishmanial activity in heterocycles; results of their in vivo and in vitro bioevaluations. Indian J Med Res 89:439-444 (Pubitemid 20083506)
5. Buates S, Matlashewski G (1999) Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: efficacy and mode of action. J Infect Dis 179:1485-1494 (Pubitemid 29246599)
6. Colakoglu M, Yaylali G, Colakoglu NY, Yalmaz M (2006) Successful treatment of visceral leishmaniasis with fluconazole and allopurinol in a patient with renal failure. Scand J Infect Dis 38:208-210
7. Croft SL, Yardley V (2002) Chemotherapy of leishmaniasis. Curr Pharmaceutic Des 8:319-342 (Pubitemid 34460464)
8. Dalton JE, Kaye PM (2010) Immunomodulators: use in combined therapy against leishmaniasis. Expert Rev Anti Infect Ther 8:739-742
9. Dwivedi Y, Rastogi R, Garg NK, Dhawan BN (1992) Picroliv and its components kutkoside and picroside I protect liver against galactosamine induced damage in rats. Pharmacol Toxicol 71:383-387
10. Griensven J, Balasegaram M, Meheus F, Alvar J, Lynen L, Boelaert M (2010) Combination therapy for visceral leishmaniasis. Lancet Infect Dis 10:184-94
11. Gupta S, Ramesh SSC, Shrivastava VML (2005) Efficacy of picroliv combination with miltefosine, an orally effective antileishmanial drug against experimental visceral leishmaniasis. Acta Trop 94:41-47
12. Gupta L, Talwar A, Nishi PS, Gupta S, Chauhan PMS (2007) Synthesis of marine alkaloid 8,9 dihydrocoscinamide B and its analogues as a novel class of antileishmanial agents. Bioorg Med Chem Lett 17:4075-4079
13. Jha BB (1998) Fluconazole in visceral leishmaniasis. Indian Pediatr 35:268-269
14. Murray HW, Berman JD, Wright SD (1988) Immunotherapy for intracellular L. donovani infection: gamma interferon plus pentavalent antimony. J Infect Dis 157:973-978
15. Mussi SV, Fernandes AP, Ferreira LAM (2007) Comparative study of the efficacy of formulations containing fluconazole or paromomycin for topical treatment of infections by Leishmania (Leishmania) major and Leishmania (Leishmania) amazonensis. Parasitol Res 100:1221-1226 (Pubitemid 46450539)
16. Puri A, Saxena RP, Guru PY, Kulshreshtha DK, Saxena KC, Dhawan BN (1992) Immunostimulant activity of Picroliv, the iridoid glycoside fraction of P. kurroa and its protective action against L. donovani infection in hamsters. Planta Med 58:528-532 (Pubitemid 23074542)
17. Rajeshkumar NV, Kuttan R (2000) Inhibition of N-nitrosodiethylamine- induced hepatocarcinogenesis by picroliv. J Exp Clin Cancer Res 19:459-465
18. Ray A, Chaudhuri SR, Majumdar B, Bandyopadhyay SK (2002) Antioxidant activity of ethanol extract of rhizome of P. kurroa on indomethacin-induced gastric ulcer during healing. Ind J Clin Biochem 17:44-51
19. Sane SA, Shakya N, Haq W, Gupta S (2010) CpG oligodeoxynucleotide augments the antileishmanial activity of miltefosine against experimental visceral leishmaniasis. J Antimicro Chemother 65:1448-1454
20. Seifert K, Croft SL (2006) In vitro and in vivo interactions between miltefosine and other antileishmanial drugs. Antimicrob Agents Chemother 50:73-79
21. Sharma P, Raghavan SAV, Saini R, Dikshit M (2004) Ascorbate-mediated enhancement of reactive oxygen species generation from polymorphonuclear leukocyte: modulatory effect of nitric oxide. J Leukocyte Biol 75:1070-1078 (Pubitemid 38720649)
22. Shrivastava JK, Misra A, Sharma P, Srivastava B, Naik S, Dube A (2003) Prophylactic potential of autoclaved L. donovani with BCG against experimental visceral leishmaniasis. Parasitol 127:107-114 (Pubitemid 37056119)
23. Srinivas N, Palne S, Nishi GS, Bhandari K (2009) Aryloxy cyclohexyl imidazoles: a novel class of antileishmanial agents. Bioorg Med Chem 19(324):327
24. Sundar S, Singh VP, Agrawal NK, Gibbs DL, Murray HW (1996) Treatment of kala-azar with oral fluconazole. Lancet 348 (9027):614
25. Torrus D, Boix V, Massa B, Portilla J, Perez-Mateo M (1996) Fluconazole plus allopurinol in treatment of visceral leishmaniasis. J Antimicrob Chemother 37:1042-1043 (Pubitemid 26158798)
26. Verma PC, Vaishali B, Gupta V, Saxena G, Rahman LU (2009) Pharmacology and chemistry of a potent hepatoprotective compound picroliv isolated from the roots and rhizomes of Picrorhiza kurroa Royle ex Benth. (Kutki). Curr Pharmaceut Biotec 10:641-649
27. Walrand S, Valeix S, Rodriguez C, Ligot P, Chassagne J, Vasson MP (2003) Flow cytometry study of polymorphonuclear neutrophiloxidative burst: a comparison of three fluorescent probes. Clin Chem Acta 331:103-110 (Pubitemid 36412031)